TABLE 4.
Resistance profiles of EC251 and EC3006 and their respective transconjugants and clonesa
| Antibiotic | MIC (μg/ml)
|
|||||||
|---|---|---|---|---|---|---|---|---|
| HB101 | DH5α | EC251 | HB101 251TC | DH5α (pBG251) | EC3006 | HB101 3006TC | DH5α(pBG3006) | |
| AMX | 4 | ≤2 | >64 | >64 | >64 | >64 | >64 | >64 |
| AMX-CLAV | 4 | ≤2 | 32 | 16 | 32 | 32 | 16 | 32 |
| TIC | ≤4 | ≤4 | >128 | >128 | >128 | >128 | >128 | >128 |
| PIP | ≤4 | ≤4 | >128 | 64 | >128 | >128 | >128 | >128 |
| PIP-TZ | ≤4 | ≤4 | 128 | 16 | >128 | >128 | 128 | >128 |
| CZ | 2 | 1 | 16 | 4 | 32 | >256 | 32 | 256 |
| CZ-CLAV | 1 | 1 | 4 | 1 | 1 | 2 | 1 | 1 |
| CXM | 4 | 2 | 32 | 8 | 64 | 32 | 8 | 16 |
| CXM-CLAV | 2 | 1 | 16 | 4 | 4 | 16 | 4 | 2 |
| FOX | 4 | 2 | 32 | 4 | 2 | 16 | 4 | 2 |
| CPD | 1 | 0.5 | 4 | 1 | 16 | 4 | 1 | 2 |
| CPD-CLAV | 0.5 | 0.5 | 2 | 0.5 | 0.5 | 2 | 0.5 | 0.25 |
| CAZ | 0.5 | 0.25 | 0.5 | 0.25 | 0.25 | 1 | 0.5 | 0.5 |
| CAZ-CLAV | 0.25 | 0.25 | 0.25 | 0.25 | 0.12 | 0.5 | 0.25 | 0.25 |
| CTX | 0.12 | 0.06 | 1 | 0.5 | 4 | 0.5 | 0.12 | 0.12 |
| CTX-CLAV | 0.12 | 0.06 | 0.25 | 0.12 | 0.12 | 0.5 | 0.06 | 0.06 |
| ATM | 0.25 | 0.06 | 0.5 | 0.12 | 0.5 | 0.5 | 0.25 | 0.12 |
| ATM-CLAV | 0.12 | 0.06 | 0.5 | 0.12 | 0.06 | 0.25 | 0.12 | 0.12 |
| FEP | 0.06 | 0.06 | 2 | 1 | >32 | 0.5 | 0.12 | 0.5 |
| FEP-CLAV | 0.06 | 0.03 | 0.12 | 0.12 | 0.25 | 0.12 | 0.06 | 0.12 |
a
EC251 and its corresponding transconjugant (HB101 251TC) and clone [DH5α (pBG251)] harbored an OXA-30 β-lactamase (see characterization of phenotype C) and EC3006 and its corresponding transconjugant (HB101 3006TC) and clone [DH5α (pBG3006)] harbored a TEM-1 β-lactamase.